ISL
LPCN icon

Ingalls & Snyder LLC’s Lipocine LPCN Stock Holding History

Ingalls & Snyder LLC’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,773
Closed -$389K – 373
2015
Q4 		$389K Sell
1,773
-10
-0.6% -$2.1K 0.02% 255
2015
Q3 		$358K Sell
1,783
-1,086
-38% -$251K 0.02% 257
2015
Q2 		$418K Buy
2,869
+301
+12% +$37.4K 0.02% 252
2015
Q1 		$301K Sell
2,568
-11
-0.4% -$1.2K 0.02% 288
2014
Q4 		$230K Sell
2,579
-240
-9% -$20.3K 0.01% 327
2014
Q3 		$292K Buy
2,819
+473
+20% +$58.8K 0.02% 296
2014
Q2 		$243K Buy
+2,346
New +$281K 0.01% 328

Other funds holding LPCN

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Ingalls & Snyder LLC's LPCN Position: Q1 2016 in Review

Ingalls & Snyder LLC sold out of Lipocine (LPCN) in Q1 2016, closing a stake of 1,773 shares — an estimated $389K sold.

Ingalls & Snyder LLC first reported a position in LPCN in Q2 2014 and held it in 7 quarters. The position peaked at $418K in Q2 2015. 53 funds tracked by Wall St. Rank hold LPCN as of Q1 2016.

  • Ingalls & Snyder LLC reported no remaining Lipocine position as of Q1 2016 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 1,773 Lipocine shares in Q1 2016, an estimated $389K.
  • Ingalls & Snyder LLC first reported a position in Lipocine in Q2 2014 and held it in 7 quarters.
  • Ingalls & Snyder LLC's Lipocine position peaked at $418K in Q2 2015.
  • 53 funds tracked by Wall St. Rank held Lipocine as of Q1 2016.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2016, filed 29 Apr 2016.